Posters

Efficacy and safety of intravitreal injection of conbercept combined with filtration surgery for neovascular glaucoma

Poster Details

First Author: J.Yang CHINA

Co Author(s):    Y. Li   K. Zhou   H. Tan              

Abstract Details

Purpose:

To assess the efficacy and safety of intravitreal conbercept combined with filtration surgery, with/without panretinal photocoagulation (PRP), for neovascular glaucoma (NVG).

Setting:

The prospective and interventional case series.

Methods:

Thirteen patients (13 eyes) of neovascular glaucoma had performed filtration surgery, including trabeculectomy and ExPress shunt, after intravitreal injection of conbercept (0.5 mg/0.05 ml) between 3 and 7 days, which angle and iris neovascularization was lightened or disappeared. Then patients were treated with panretinal photocoagulation, unless refractive medium was opacity. The best-corrected visual acuity (BCVA), intraocular pressure (IOP), the number of antiglaucoma medications and complications were recorded at baseline and each follow-up.

Results:

The mean duration of follow-up was 0.9±0.5 years. The mean IOP was 42.1±11.6 mm Hg at baseline. The surgical success rate was 91.7%, 76.9%, 84.6% and 69.2% at 1 week, 1 month, 3 months and final follow-up, respectively. Nine eyes were undergone trabeculectomy, which 7 eyes (77.8%) were successful, while 4 eyes undergone ExPress shunt, only 2 eyes (50.0%) were successful. The mean number of antiglaucoma medications was 1.2±0.7, and the mean IOP was 18.5±8.3 mm Hg at the final follow-up. Eight eyes were undergone PRP, which final IOP in 7 patients (87.5%) was normal, while IOP in 2 eyes (40.0%) was normal in patients without PRP. Postoperative complications mainly include hyphema in the anterior chamber (5 eyes), shallow anterior chamber (3 eyes), vitreous hemorrhage (2 eyes), choroidal effusion (1 eye).

Conclusions:

Intravitreal injection of conbercept is effectively and safely adjutant procedure for patients with NVG who performed filtration surgery. Tabeculectomy seems more effective than EsPress shunt in NVG patients.

Financial Disclosure:

None